UC Irvine to Validate MicroRNA Dx Tests for Rosetta Genomics | GenomeWeb
NEW YORK (GenomeWeb News) – Rosetta Genomics said today it has struck an agreement with the University of California, Irvine, School of Medicine to work together to validate diagnostic tests based on the company’s microRNA technology.
 
Under the agreement, the CLIA-certified medical school and the company will work together to validate tests that are designed to differentiate squamous from non-squamous lung cancer and to differentiate mesothelioma from adenocarcinoma, as well as to identify cancers of unknown primary origin.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.